Trial Profile
A retrospective study of Regorafenib tolerance and outcomes in inner-city minority colorectal cancer population
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Feb 2018
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Feb 2018 New trial record
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium